HIV-related lipodystrophy and facial lipoatrophy: The role of Restylane SubQ in reversing facial wasting

Aesthetic Surgery Journal

Volumn 26, Issue 1 SUPPL., 2006, Pages

  Strand, Anders ^a   Wolters, Marianne ^b  

^a Q Med AB   (Sweden)

^b Gemeinschaftspraxis fur Plastische Chirurgie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ANTIRETROVIRUS AGENT; COLLAGEN IMPLANT; FILLER; HYALURONIC ACID; POLYACRYLAMIDE GEL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; BODY FAT DISTRIBUTION; CROSS RESISTANCE; DISEASE EXACERBATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG CHOICE; DRUG MECHANISM; DRUG USE; DYSLIPIDEMIA; FACE DEFORMITY; FATALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INSULIN RESISTANCE; LIFE EXPECTANCY; LIPID COMPOSITION; LIPOATROPHY; METABOLIC DISORDER; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SAFETY; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; SELF ESTEEM; SIDE EFFECT; SOCIAL ASPECT; SOCIAL INTERACTION; SOFT TISSUE; TREATMENT REFUSAL; VIRUS LOAD; VIRUS RESISTANCE;

EID: 33644640184     PISSN: 1090820X     EISSN: 1527330X     Source Type: Journal    
DOI: 10.1016/j.asj.2005.08.002     Document Type: Article

References (31)

1. E Collins C Wagner S Walmsley Psychosocial impact of the lipodystrophy syndrome in HIV infection AIDS Read 10 2000 546-550
2. J James A Carruthers J Carruthers HIV-associated facial lipoatrophy Dermatol Surg 28 2002 979-986
3. PW Mallon J Miller DA Cooper A Carr Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy AIDS 17 2003 971-979
4. T Saint-Marc M Partisani I Poizot-Martin O Rouviere F Bruno R Avellaneda et. al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study AIDS 14 2000 37-49
5. MP Dube R Zackin P Tebas R Roubenoff K Mulligan G Robbins et. al. Prospective study of regional body composition in antiretroviral-naïve subjects randomized to receive zidovudine + lamivudine or didanosine + stavudine combined with nelfinavir, efavirenz, or both: A5005s, a study of ACTG 384 Antivir Ther 2002 L18
6. KA Lichtenstein DJ Ward AC Moorman KM Delaney B Young FJ Palella Jr et. al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population AIDS 15 2001 1389-1398
7. E Bernasconi K Boubaker C Junghans M Flepp HJ Furrer A Haensel et. al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort study J Acquir Immune Defic Syndr 31 2002 50-55
8. J Miller A Carr S Emery M Law S Mallal D Baker et. al. HIV lipodystrophy: Prevalence, severity and correlates of risk in Australia HIV Med 4 2003 293-301
9. A Carr K Samaras A Thorisdottir GR Kaufmann DJ Chisholm DA Cooper Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study Lancet 353 1999 2093-2099
10. C Gervasoni AL Ridolfo G Trifiro S Santambrogio G Norbiato M Musicco et. al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy AIDS 13 1999 465-471
11. M Dowell C Flexner PO Kwiterovich MD Lane Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors J Biol Chem 275 2000 41325-41332
12. JM Lenhard ES Furfine RG Jain O Ittoop LA Orband-Miller SG Blanchard et. al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro Antiviral Res 47 2000 121-129
13. M Caron M Auclair H Sterlingot M Kornprobst J Capeau Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation AIDS 17 2003 2437-2444
14. P Reiss M Casula A de Ronde GJ Weverling J Goudsmit JM Lange Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs single (zidovudine) nucleoside reverse transcriptase inhibitors HIV Med 5 2004 11-14
15. D Nolan E Hammond A Martin L Taylor S Herrmann E McKinnon et. al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy AIDS 17 2003 1329-1338
16. R Roche I Poizot-Martin CM Yazidi E Compe JA Gastaut J Torresani et. al. Effects of antiretroviral drug combinations on the differentiation of adipocytes AIDS 16 2002 13-20
17. ML Gougeon L Penicaud B Fromenty P Leclercq JP Viard J Capeau Adipocytes: Targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations Antivir Ther 9 2004 161-177
18. MA Valantin C Aubron-Olivier J Ghosn E Laglenne M Pauchard H Schoen et. al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA AIDS 17 2003 2471-2477
19. M John EJ McKinnon IR James DA Nolan SE Herrmann CB Moore et. al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients J Acquir Immune Defic Syndr 33 2003 29-33
20. J Cofrancesco T Brown CR Martins Management options for facial lipoatrophy AIDS Read 14 2004 645-650
21. L Bauman CosmoDerm/CosmoPlast (human bioengineered collagen) for the aging face Facial Plast Surg 20 2004 125-128
22. PM Friedman EA Mafong AN Kauvar RG Geronemus Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft-tissue augmentation Dermatol Surg 28 2002 491-494
23. GJ Moyle L Lysakova S Brown N Sibtain J Healy C Priest et. al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection HIV Med 5 2004 82-87
24. D Vochelle The use of poly-L-lactic acid in the management of soft-tissue augmentation: A five-year experience Semin Cutan Med Surg 23 2004 223-226
25. CM Burgess RM Quiroga Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy J Am Acad Dermatol 52 2005 233-239
26. SJ Dijkema B van der Lei RE Kibbelaar New-fill injections may induce late-onset foreign body granulomatous reaction Plast Reconstr Surg 115 2005 76e-78e
27. C Protopapa G Sito D Caporale N Cammarota Bio-Alcamid in drug-induced lipodystrophy J Cosmet Laser Ther 5 2003 226-230
28. BL Claoue P Rabineau The polyalkylimide gel: Experience with Bio-Alcamid Semin Cutan Med Surg 23 2004 236-240
29. DH Jones A Carruthers D Orentreich HJ Brody MY Lai S Azen et. al. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: An open pilot trial Dermatol Surg 30 2004 1279-1286
30. SR Coleman Structural Fat Grafting 2004 Quality Medical Publishing St. Louis
31. B Strauch T Baum N Robbins Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area Plast Reconstr Surg 113 2004 363-370